Analysis:
### (a) Source analysis (summary, quality, date, and what’s “fact” vs “opinion”)

1) **Metaculus community prediction scrape (as of 2026-03-01 / viewed 2026-03-03)**
- **What it says (facts):** Current community prediction is **26.0%** with **289 forecasters**; **7-day change +1 pp**, **14-day -1 pp**, **30-day -4 pp**; historical range **[16%, 66%]**.
- **Quality:** High for *this* meta-question because it’s direct platform state; however it’s a snapshot and the “trend” stats don’t tell us volatility distribution.
- **Relevance:** Central—this is the only source that directly constrains the meta-event (crossing 27% by 2026-03-13).

2) **Wikipedia: CRISPR gene editing / Sickle cell disease / Beta thalassemia / HSC / Fetal hemoglobin**
- **What it says (facts, but background-level):** Confirms the 2023 approvals for SCD and β-thalassemia; describes mechanism (HbF derepression), and that trials exist in other conditions.
- **Quality:** Medium as encyclopedic background; not tailored to 2026 pipelines; may lag fast-moving regulatory details.
- **Relevance to *meta* question:** Indirect; doesn’t inform how Metaculus CP will move over the next 10 days.

3) **EA Forum post on Metaculus AI track record (Metaculus performance analysis)**
- **What it says:** Reports Brier scores and aggregation methods (time-weighted median; “Metaculus Prediction” does extremization/performance weighting).
- **Quality:** Medium-high for general platform behavior, but domain mismatch (AI questions) and not about short-horizon CP volatility.
- **Relevance:** Slight—helps set expectations that CP can be “sticky” (median-based) but still responsive.

4) **Rethink Priorities analysis of resolved AI predictions**
- **What it says (facts + interpretation):** Finds weak evidence of slight optimism bias in binary questions (predicting more “Yes” than occurred) in that AI subset.
- **Quality:** Medium; careful analysis but again domain mismatch (AI, not biomed) and doesn’t quantify 10-day moves.
- **Relevance:** Slight—suggests a possible mild “progress optimism,” but it’s not a strong tether for a 10-day CP movement call.

5) **TribecaKnowledge blog on 2025 drug approvals & regulatory disruptions**
- **What it says (facts, if accurate):** 2025 saw fewer approvals; FDA staffing disruptions/government shutdown; some reform rhetoric.
- **Quality:** Medium-low to medium (blog; unclear methodology; but plausible macro context).
- **Relevance:** Weak for the *meta* question; could indirectly nudge forecasters down on regulatory optimism, but not a strong predictor of a 1 pp move in 10 days.

6) **Market research / vendor content (Ken Research; Statifacts/GlobeNewswire; IDT article)**
- **What it says:** Broad growth narratives; general claims that approvals are increasing/streamlining; one statistic “7 out of 100 CGT therapies” (context unclear and not gene-editing-specific).
- **Quality:** Low-medium (commercial incentives; often vague; not resolution-criteria-specific).
- **Relevance:** Low for near-term Metaculus CP movement.

7) **Agent report on late-move frequencies on Metaculus**
- **What it says (facts):** Confirms Metaculus API availability and *qualitative* triggers for abrupt moves (regulatory press releases, trial readouts, leaks, adverse events). **Explicitly notes missing quantitative stats** for “>1 pp move in last 10 days.”
- **Quality:** Medium—useful methodological note, but no numeric base rate extracted.
- **Relevance:** Moderate conceptually: in the absence of “breaking news,” large step-changes are less likely; but it doesn’t quantify how much less.

---

### (b) Reference class analysis (what base rates to use)

Because the question is **not** “Will a gene-editing approval happen?”, but rather **“Will Metaculus CP be >27% on a particular date?”**, the best reference classes are about **short-horizon CP movements**:

1) **Metaculus binary CP crossing a nearby threshold (±1 pp) within ~10 days**  
- **Pros:** Directly matches the meta structure (threshold crossing).
- **Cons:** We lack extracted historical stats in provided sources; must reason from general properties (median aggregation + typical update cadence).

2) **Metaculus biotech/regulatory questions’ CP volatility in final ~2 weeks**  
- **Pros:** Domain-matched; these questions can jump on official announcements.
- **Cons:** Still no quantified base rate here; and our window is very short relative to the underlying 2026 event.

3) **Generic Metaculus short-window “CP rise above X” metas**  
- **Pros:** Closest in mechanics; threshold-crossing behavior often driven by participation/noise rather than new information.
- **Cons:** Again, no hard frequency stats provided.

**Most suitable (given what we have):** (1) threshold-crossing within ~10 days, supplemented by (2) qualitative “news shock” considerations.

---

### (c) Timeframe analysis

- **Today:** 2026-03-03  
- **Target timestamp:** 2026-03-13 15:41:01  
- **Time left:** ~**10 days**

In ~10 days, absent a major news catalyst, Metaculus CPs (especially a **time-weighted median**) often move **incrementally**, mainly from:
- a trickle of new forecasts,
- occasional comment-driven reassessments,
- mild drift as time passes without confirming events.

But biotech/regulatory topics *can* see abrupt moves if there’s a trial readout / regulator signal. The provided materials don’t identify any such imminent catalyst—so the outside view should weight **“no major shock”** relatively heavily.

---

### (d) Justification (outside view synthesis)

Key quantitative anchor: CP is **26.0%**, and we need **>27.0%** at the target time—i.e., a net move of **more than +1.0 percentage point** from the current value.

Outside-view considerations:
- **Small threshold gap:** +1 pp is not huge; it’s plausibly reachable via normal forecast churn.
- **But current directionality is mixed:** last **7 days +1 pp** (helpful), but last **30 days -4 pp** (suggesting an overall recent downward drift).
- **Aggregation stickiness:** a time-weighted median with many forecasters can be somewhat resistant to small numbers of new predictions, *unless* the distribution of forecasts is dense around the high-20s (in which case even modest new mass can tip the median).
- **Base expectation absent news:** with no identified trigger, I’d expect **slight downward drift or flatness** rather than a sustained rise, because the underlying event is a “during 2026” approval and as time passes without concrete regulatory milestones, forecasters often shade down.

So the outside view is: **crossing upward is plausible but not the modal outcome**. I’d put it in the “one-third-ish” range rather than near 50%.

Outside view calibration:
- I want a probability that reflects the real frequency of “>1 pp net upward move over ~10 days” from a starting point slightly below a threshold, under mixed recent trends.
- A reasonable rough model is that the 10-day CP change has **moderate noise (a few percentage points)** but **near-zero to slightly negative drift** in the absence of news. Under that kind of distribution, exceeding +1 pp is meaningfully less than 50%, more like **25–40%**.
- Given the observed recent *short-term* uptick (+1 pp over 7 days) but *medium-term* decline (-4 pp over 30 days), I center near the middle of that range.

Outside View Prediction:
**34.2%**